The Promise Of Youth, The Reality Of Aging
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they鈥檙e compelled to use off-label meds as research goes unfunded.
FDA
381-400 of 477 results
-
-
Patients Question How FDA Approves Medical Devices
High-profile failures of implantable medical devices 鈥 such as certain hip joints and pelvic mesh 鈥 have prompted the Food and Drug Administration to revise its assessment process.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 How Safe Are Your Supplements?
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
-
A 鈥楩ountain Of Youth鈥 Pill? Sure, If You鈥檙e A Mouse.
The race for the cure to aging sparks hope and hype among top scientists 鈥 plus billions of dollars in investment.
-
John Dingell, 鈥楧ean Of The House,’ Remembered As A Force In Health Policy
The Michigan Democrat chaired the House Energy and Commerce Committee and his impact on health care was immense.
By Julie Rovner -
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren鈥檛 For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven鈥檛 reached the market.
By Sydney Lupkin and Jay Hancock -
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 New Year, New Health Proposals
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and, for 鈥渆xtra credit,鈥 provide their favorite health policy stories of the week. Rovner also interviews KHN鈥檚 Jordan Rau about the latest 鈥淏ill of the Month.鈥
-
Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment
Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.
By Liz Szabo -
Tainted Drugs
When Medicine Makes Patients Sicker
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents 鈥 inspection records, recalls, warning letters and lawsuits 鈥 reveals how drugs that are poorly manufactured or contaminated can reach consumers.
-
How The Government Shutdown Affects Health Programs
Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.
-
5 Ways Nixing The Affordable Care Act Could Upend The Entire Health System
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
By Julie Rovner -
Why The U.S. Remains The World’s Most Expensive Market For 鈥楤iologic鈥 Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from 鈥渂iosimilars.鈥 It鈥檚 a very different story in Europe.
-
In Grandma鈥檚 Stocking: An Apple Watch To Monitor Falls, Track Heart Rhythms
The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Apple鈥檚 target audience beyond the usual, tech-savvy, early adopters to those with older tickers.
By Rachel Bluth -
Government Investigation Finds Flaws In the FDA鈥檚 Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
By Sarah Jane Tribble and Sydney Lupkin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Reading The Tea Leaves In Blue Wave鈥檚 Wake
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN鈥檚 Jay Hancock about the latest 鈥淏ill of the Month.鈥
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Health Nerd Books For The Holidays
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a 鈥淢edicare-for-all鈥 bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
-
Fish Oil Drug Looks Heart-Healthy. Just Don鈥檛 Swallow It Hook, Line And Sinker.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn鈥檛 find the same promise for over-the-counter fish oil supplements when tested in healthy people.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Heart Drug Spotlights Troubling Trends In Drug Marketing
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.